VUNO stock surges for consecutive days on entry into China’s medical AI market, up 17% early in session [Stock NOW]

[Financial News] VUNO, a medical AI company, has been posting sharp gains for consecutive days amid expectations that it will expand into the Chinese market in earnest.
Investor sentiment appears to have been boosted by VUNO’s exclusive sales agreement for its AI-based cardiac arrest prediction medical device, VUNO Med-DeepCARS, in Hainan Province, as well as news of expanded local operations for its fundus-image diagnostic assistance solution.
As of 9:16 a.m. on the 29th, VUNO was trading at 8,030 won, up 1,210 won, or 17.74%, from the previous trading day. It briefly reached 8,240 won during the session, widening its gain to the 20% range.
Previously, VUNO closed at 7,240 won on the 28th, up 29.98% from the previous trading day. After gaining 8.93% on the 23rd, the stock continued its steep upward trend, hitting the daily upper limit on the 28th.
The news of VUNO’s entry into China’s medical AI market is being cited as a key driver of the stock’s rise. VUNO announced on the 28th that it had signed an exclusive sales agreement with Chinese medical company Guolun for VUNO Med-DeepCARS, its AI-based cardiac arrest prediction medical device, in Hainan Province. The agreement has a two-year term, and the two companies will pursue exclusive sales in Hainan Province.
VUNO is also expanding its local business for VUNO Med-Fundus AI, a medical device that assists with diagnosis using fundus images. The company is pursuing the product’s adoption in Yangzhou, Jiangsu Province, in cooperation with Chinese medical company BioVision. After integrating the device with BioVision’s chronic disease management platform, VUNO began using it at local public medical institutions. The two companies plan to begin sales after conducting local testing.
Fundus AI is an AI medical device that analyzes fundus images and presents 12 abnormal findings relevant to diagnosis. It is used to identify complications from chronic diseases such as diabetic retinopathy and is expected to see demand mainly at primary care institutions, where access to ophthalmologists is relatively limited.
[email protected] Kang Jung-mo Reporter